Full-dose gemcitabine is a more effective chemotherapeutic agent than 5-fluorouracil for concurrent chemoradiotherapy as first-line treatment in locally advanced pancreatic cancer

Huapyong Kang, Jee Suk Chang, Tak Geun Oh, Moon Jae Chung, Jeong Youp Park, Seung Woo Park, Jinsil Seong, Si Young Song, Jae Bok Chung, Seungmin Bang

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Objectives: To compare the efficacy of full-dose gemcitabine-based concurrent chemoradiotherapy (FG-CCRT) and conventional 5-fluorouracil CCRT (5FU-CCRT) for locally advanced pancreatic cancer (LAPC). Methods: 109 LAPC cases treated with FG-CCRT (n = 89) or 5FU-CCRT (n = 20) were reviewed retrospectively. The FG-CCRT group was composed of a full-dose gemcitabine monotherapy (1,000 mg/m2) arm and a combination therapy with cisplatin (70 mg/m2) arm. The 5FU-CCRT group used a radiosensitizing dose of 5-FU (500 mg/m2) plus leucovorin (20 mg/m2). Concurrent radiotherapy was targeted at the tumor with a 5-mm margin without lymph node irradiation. Results: Objective response rate (ORR) and disease control rate (DCR) was significantly higher in the FG-CCRT group (ORR: 32.6 vs. 5%, p = 0.013; DCR: 79.8 vs. 50.0%, p = 0.006). FG-CCRT showed remarkable superiority to 5FU-CCRT for suppressing distant metastasis (18.0 vs. 45.0%, p = 0.017). Neutropenia (34.8 vs. 10%, p = 0.032) and thrombocytopenia (21.3 vs. 0.0%, p = 0.021) were more frequent in the FG-CCRT group as originally expected. When dividing the FG-CCRT group to gemcitabine monotherapy (GEM) and gemcitabine plus cisplatin, toxicities of the GEM subgroup were not different than those of the 5FU-CCRT group. Conclusion: FG-CCRT, especially full-dose gemcitabine monotherapy-based CCRT was more effective for the initial control of LAPC than 5FU-CCRT, and also relatively safe.

Original languageEnglish
Pages (from-to)191-199
Number of pages9
JournalChemotherapy
Volume60
Issue number3
DOIs
Publication statusPublished - 2014 Jan 1

Fingerprint

gemcitabine
Chemoradiotherapy
Pancreatic Neoplasms
Fluorouracil
Therapeutics
Cisplatin

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pharmacology
  • Drug Discovery
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Kang, Huapyong ; Chang, Jee Suk ; Oh, Tak Geun ; Chung, Moon Jae ; Park, Jeong Youp ; Park, Seung Woo ; Seong, Jinsil ; Song, Si Young ; Chung, Jae Bok ; Bang, Seungmin. / Full-dose gemcitabine is a more effective chemotherapeutic agent than 5-fluorouracil for concurrent chemoradiotherapy as first-line treatment in locally advanced pancreatic cancer. In: Chemotherapy. 2014 ; Vol. 60, No. 3. pp. 191-199.
@article{cbc2a5bfd3994e82960175ace9ec16c6,
title = "Full-dose gemcitabine is a more effective chemotherapeutic agent than 5-fluorouracil for concurrent chemoradiotherapy as first-line treatment in locally advanced pancreatic cancer",
abstract = "Objectives: To compare the efficacy of full-dose gemcitabine-based concurrent chemoradiotherapy (FG-CCRT) and conventional 5-fluorouracil CCRT (5FU-CCRT) for locally advanced pancreatic cancer (LAPC). Methods: 109 LAPC cases treated with FG-CCRT (n = 89) or 5FU-CCRT (n = 20) were reviewed retrospectively. The FG-CCRT group was composed of a full-dose gemcitabine monotherapy (1,000 mg/m2) arm and a combination therapy with cisplatin (70 mg/m2) arm. The 5FU-CCRT group used a radiosensitizing dose of 5-FU (500 mg/m2) plus leucovorin (20 mg/m2). Concurrent radiotherapy was targeted at the tumor with a 5-mm margin without lymph node irradiation. Results: Objective response rate (ORR) and disease control rate (DCR) was significantly higher in the FG-CCRT group (ORR: 32.6 vs. 5{\%}, p = 0.013; DCR: 79.8 vs. 50.0{\%}, p = 0.006). FG-CCRT showed remarkable superiority to 5FU-CCRT for suppressing distant metastasis (18.0 vs. 45.0{\%}, p = 0.017). Neutropenia (34.8 vs. 10{\%}, p = 0.032) and thrombocytopenia (21.3 vs. 0.0{\%}, p = 0.021) were more frequent in the FG-CCRT group as originally expected. When dividing the FG-CCRT group to gemcitabine monotherapy (GEM) and gemcitabine plus cisplatin, toxicities of the GEM subgroup were not different than those of the 5FU-CCRT group. Conclusion: FG-CCRT, especially full-dose gemcitabine monotherapy-based CCRT was more effective for the initial control of LAPC than 5FU-CCRT, and also relatively safe.",
author = "Huapyong Kang and Chang, {Jee Suk} and Oh, {Tak Geun} and Chung, {Moon Jae} and Park, {Jeong Youp} and Park, {Seung Woo} and Jinsil Seong and Song, {Si Young} and Chung, {Jae Bok} and Seungmin Bang",
year = "2014",
month = "1",
day = "1",
doi = "10.1159/000375402",
language = "English",
volume = "60",
pages = "191--199",
journal = "Chemotherapy",
issn = "0009-3157",
publisher = "S. Karger AG",
number = "3",

}

Full-dose gemcitabine is a more effective chemotherapeutic agent than 5-fluorouracil for concurrent chemoradiotherapy as first-line treatment in locally advanced pancreatic cancer. / Kang, Huapyong; Chang, Jee Suk; Oh, Tak Geun; Chung, Moon Jae; Park, Jeong Youp; Park, Seung Woo; Seong, Jinsil; Song, Si Young; Chung, Jae Bok; Bang, Seungmin.

In: Chemotherapy, Vol. 60, No. 3, 01.01.2014, p. 191-199.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Full-dose gemcitabine is a more effective chemotherapeutic agent than 5-fluorouracil for concurrent chemoradiotherapy as first-line treatment in locally advanced pancreatic cancer

AU - Kang, Huapyong

AU - Chang, Jee Suk

AU - Oh, Tak Geun

AU - Chung, Moon Jae

AU - Park, Jeong Youp

AU - Park, Seung Woo

AU - Seong, Jinsil

AU - Song, Si Young

AU - Chung, Jae Bok

AU - Bang, Seungmin

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Objectives: To compare the efficacy of full-dose gemcitabine-based concurrent chemoradiotherapy (FG-CCRT) and conventional 5-fluorouracil CCRT (5FU-CCRT) for locally advanced pancreatic cancer (LAPC). Methods: 109 LAPC cases treated with FG-CCRT (n = 89) or 5FU-CCRT (n = 20) were reviewed retrospectively. The FG-CCRT group was composed of a full-dose gemcitabine monotherapy (1,000 mg/m2) arm and a combination therapy with cisplatin (70 mg/m2) arm. The 5FU-CCRT group used a radiosensitizing dose of 5-FU (500 mg/m2) plus leucovorin (20 mg/m2). Concurrent radiotherapy was targeted at the tumor with a 5-mm margin without lymph node irradiation. Results: Objective response rate (ORR) and disease control rate (DCR) was significantly higher in the FG-CCRT group (ORR: 32.6 vs. 5%, p = 0.013; DCR: 79.8 vs. 50.0%, p = 0.006). FG-CCRT showed remarkable superiority to 5FU-CCRT for suppressing distant metastasis (18.0 vs. 45.0%, p = 0.017). Neutropenia (34.8 vs. 10%, p = 0.032) and thrombocytopenia (21.3 vs. 0.0%, p = 0.021) were more frequent in the FG-CCRT group as originally expected. When dividing the FG-CCRT group to gemcitabine monotherapy (GEM) and gemcitabine plus cisplatin, toxicities of the GEM subgroup were not different than those of the 5FU-CCRT group. Conclusion: FG-CCRT, especially full-dose gemcitabine monotherapy-based CCRT was more effective for the initial control of LAPC than 5FU-CCRT, and also relatively safe.

AB - Objectives: To compare the efficacy of full-dose gemcitabine-based concurrent chemoradiotherapy (FG-CCRT) and conventional 5-fluorouracil CCRT (5FU-CCRT) for locally advanced pancreatic cancer (LAPC). Methods: 109 LAPC cases treated with FG-CCRT (n = 89) or 5FU-CCRT (n = 20) were reviewed retrospectively. The FG-CCRT group was composed of a full-dose gemcitabine monotherapy (1,000 mg/m2) arm and a combination therapy with cisplatin (70 mg/m2) arm. The 5FU-CCRT group used a radiosensitizing dose of 5-FU (500 mg/m2) plus leucovorin (20 mg/m2). Concurrent radiotherapy was targeted at the tumor with a 5-mm margin without lymph node irradiation. Results: Objective response rate (ORR) and disease control rate (DCR) was significantly higher in the FG-CCRT group (ORR: 32.6 vs. 5%, p = 0.013; DCR: 79.8 vs. 50.0%, p = 0.006). FG-CCRT showed remarkable superiority to 5FU-CCRT for suppressing distant metastasis (18.0 vs. 45.0%, p = 0.017). Neutropenia (34.8 vs. 10%, p = 0.032) and thrombocytopenia (21.3 vs. 0.0%, p = 0.021) were more frequent in the FG-CCRT group as originally expected. When dividing the FG-CCRT group to gemcitabine monotherapy (GEM) and gemcitabine plus cisplatin, toxicities of the GEM subgroup were not different than those of the 5FU-CCRT group. Conclusion: FG-CCRT, especially full-dose gemcitabine monotherapy-based CCRT was more effective for the initial control of LAPC than 5FU-CCRT, and also relatively safe.

UR - http://www.scopus.com/inward/record.url?scp=84928427483&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928427483&partnerID=8YFLogxK

U2 - 10.1159/000375402

DO - 10.1159/000375402

M3 - Article

VL - 60

SP - 191

EP - 199

JO - Chemotherapy

JF - Chemotherapy

SN - 0009-3157

IS - 3

ER -